Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 3;24(3):2978.
doi: 10.3390/ijms24032978.

Recent Advancements in Topical Anti-Psoriatic Nanostructured Lipid Carrier-Based Drug Delivery

Tulshidas S Patil  1 , Nayan A Gujarathi  1 , Abhijeet A Aher  1 , Hemal E Pachpande  1 , Charu Sharma  2 , Shreesh Ojha  3 , Sameer N Goyal  1 , Yogeeta O Agrawal  1
Affiliations
Review

Recent Advancements in Topical Anti-Psoriatic Nanostructured Lipid Carrier-Based Drug Delivery

Tulshidas S Patil et al. Int J Mol Sci. .

Abstract

Psoriasis is linked with unusual differentiation and hyperproliferation of epidermal keratinocytes that significantly impair the quality of life (QoL) of patients. The present treatment options only provide symptomatic relief and are surrounded by various adverse effects. Recently, nanostructured lipid carriers (NLCs) have emerged as next-generation nanocarriers with better physicochemical characteristics. The current manuscript provides background information on psoriasis, its pathophysiology, existing treatment options, and its limitations. It highlights the advantages, rationale, and mechanism of the permeation of NLCs for the treatment of psoriasis. It further gives a detailed account of various NLC nanoformulations for the treatment of psoriasis. In addition, tabular information is provided on the most relevant patents on NLCs for treating psoriasis. Lastly, light is shed on regulatory considerations related to NLC-like nanoformulations. In the treatment of psoriasis, NLCs display a sustained release drug profile, an ability to incorporate both hydrophobic and hydrophilic drugs, an enhancement in skin hydration, penetrability, retention, and bioavailability of the drug, along with reduced staining potential as compared to conventional ointments, and decreased side effects of drug molecules. This affirms the bright future of NLC nanoformulations in the treatment of psoriasis. However, academic industry collaboration and more sound regulatory controls are required to commercialize the NLC nanoformulations for psoriasis treatment.

Keywords: nanostructured lipid carriers; pharmacological findings; physicochemical findings; psoriasis; regulatory aspects.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(A) Types of psoriasis based on clinical manifestations, anatomical site, and prevalence. (B) Common symptoms of psoriasis and percentage occurrence.
Figure 2
Figure 2
Pathophysiology of psoriasis disease.
Figure 3
Figure 3
Schematic representation of SLNs: (A) solid solution model; (B) core-shell model (drug-enriched shell); and (C) core-shell model (lipid-enriched shell) and NLCs: (D) imperfect type of drug encapsulated in a gap between fatty acid chain of solid and liquid lipids; (E) formless-type mixture of solid and liquid lipids preventing crystal formation; (F) multiple-type nanocompartments of oils containing dissolved drug.
Figure 4
Figure 4
Advantages of nanostructured lipid carriers (NLCs) over other nanocarriers.
Figure 5
Figure 5
Rationale behind the selection of NLCs for the treatment of psoriasis disease.
Figure 6
Figure 6
Mode of permeation from NLCs through psoriatic skin.
See this image and copyright information in PMC

References

    1. World Health Organization Global Report on Psoriasis 2016. [(accessed on 20 January 2023)]. Available online: https://apps.who.int/iris/handle/10665/204417.
    1. Thappa D., Munisamy M. Research on psoriasis in India: Where do we stand? Indian J. Med. Res. 2017;146:147–149. doi: 10.4103/ijmr.IJMR_1296_17. - DOI - PMC - PubMed
    1. Ferreira M. Master’s Thesis. University of Porto; Porto, Portugal: 2015. Nanostructured Lipid Carriers: A New Approach for Psoriasis Dermal Therapy; pp. 1–115.
    1. Ghate V., Kodoth A., Shah A., Vishalakshi B., Lewis S. Colloidal nanostructured lipid carriers of pentoxifylline produced by microwave irradiation ameliorates imiquimod-induced psoriasis in mice. Colloids Surf. B Biointerfaces. 2019;181:389–399. doi: 10.1016/j.colsurfb.2019.05.074. - DOI - PubMed
    1. Rapalli V., Kaul V., Waghule T., Gorantla S., Sharma S., Roy A., Dubey S., Singhvi G. Curcumin loaded nanostructured lipid carriers for enhanced skin retained topical delivery: Optimization, scale-up, in-vitro characterization and assessment of ex-vivo skin deposition. Eur. J. Pharm. Sci. 2020;152:105438. doi: 10.1016/j.ejps.2020.105438. - DOI - PubMed